Xin Lang Cai Jing·2026-02-27 08:04Core Viewpoint - Shanghai Pharmaceuticals' subsidiary, Changzhou Pharmaceutical Factory, has received a drug registration certificate from the Philippines Food and Drug Administration for the launch of Pregabalin capsules, which are approved for sale in three specifications: 50mg, 75mg, and 150mg. This approval is expected to positively impact the company's expansion into overseas markets, although there are various uncertainties that may affect sales performance [1]. Group 1 - The drug Pregabalin is primarily used for the treatment of neuropathic pain and as an adjunct therapy for epilepsy [1]. - The total sales for the same specifications of the drug in the Philippines market for 2024 are projected to be $13.37 million [1]. - The company has invested additional research and development expenses for the drug's market entry in Southeast Asia [1].